North America Diabetic Neuropathy Treatment Market
The diabetic neuropathy treatment market in North America is expected to reach a projected revenue of US$ 2,555.0 million by 2030. A compound annual growth rate of 6.6% is expected of North America diabetic neuropathy treatment market from 2024 to 2030.
- Pharmaceuticals
- Metabolic Disorders Treatment
- diabetic neuropathy treatment market report
- Metabolic Disorders Treatment
Revenue, 2023 (US$M)
$1,634.8
Forecast, 2030 (US$M)
$2,555.0
CAGR, 2024 - 2030
6.6%
Report Coverage
North America
Global Market
Related Markets
GVR research-powered AI
Ask Prism AI about the diabetic neuropathy treatment market report market
Get cited answers from GVR research on market growth, segments, regulations and forecasts.
- Source-linked answers
- Market-specific context
- Traceable figures
North America diabetic neuropathy treatment market highlights
- The North America diabetic neuropathy treatment market generated a revenue of USD 1,634.8 million in 2023.
- The market is expected to grow at a CAGR of 6.6% from 2024 to 2030.
- In terms of segment, peripheral neuropathy was the largest revenue generating disorder type in 2023.
- Autonomic Neuropathy is the most lucrative disorder type segment registering the fastest growth during the forecast period.
- Country-wise, Canada is expected to register the highest CAGR from 2024 to 2030.
North America data book summary
| Market revenue in 2023 | USD 1,634.8 million |
| Market revenue in 2030 | USD 2,555.0 million |
| Growth rate | 6.6% (CAGR from 2023 to 2030) |
| Largest segment | Peripheral neuropathy |
| Fastest growing segment | Autonomic Neuropathy |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Peripheral Neuropathy, Autonomic Neuropathy, Proximal Neuropathy, Focal Neuropathy |
| Key market players worldwide | Abbott Laboratories, Eli Lilly and Co, Pfizer Inc, Janssen Pharmaceuticals, Lupin, Astellas Pharma Inc, Glenmark Pharmaceuticals, Boehringer Ingelheim, Novartis AG ADR |
Other key industry trends
- In terms of revenue, North America region accounted for 37.7% of the global diabetic neuropathy treatment market in 2023.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 1,800.6 million by 2030.
No credit card required*
Customize the Report
20% free customization
- Include
- Countries, segments, points
- Tailor
- To your product definition
- Extend
- Deeper competitor detail
- Or
- A fully bespoke study
- Turnaround
- 5–10 working days
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Diabetic Neuropathy Treatment Market Report
Diabetic neuropathy treatment market report segmentation & scope
Diabetic Neuropathy Treatment Market Report Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Novartis AG ADR | View profile | 76,057 | Lichtstrasse 35, Basel, Switzerland, 4056 | www.novartis.com |
| Abbott Laboratories | View profile | 114,000 | 100 Abbott Park Road, Abbott Park, IL, United States, 60064-6400 | www.abbottinvestor.com |
| Pfizer Inc | View profile | 88,000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | www.pfizer.com |
| Lupin | View profile | 10001+ | Mumbai, Maharashtra, India, Asia | www.lupin.com |
| Boehringer Ingelheim | View profile | 10001+ | Ingelheim Am Rhein, Rheinland-Pfalz, Germany, Europe | www.boehringer-ingelheim.com/ |
| Eli Lilly and Co | View profile | 43,000 | Lilly Corporate Center, Indianapolis, IN, United States, 46285 | www.lilly.com |
| Astellas Pharma Inc | View profile | 14,484 | 2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo, Japan, 103-8411 | www.astellas.com |
| Janssen Pharmaceuticals | View profile | 1-10 | Titusville, New Jersey, United States, North America | www.xarelto-us.com |
| Glenmark Pharmaceuticals | View profile | 10001+ | Andheri, Maharashtra, India, Asia | www.glenmarkpharma.com |
North America diabetic neuropathy treatment market report
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Diabetic Neuropathy Treatment Market will help companies and investors design strategic landscapes.
Peripheral Neuropathy was the largest segment with a revenue share of 63.09% in 2023.
Horizon Databook has segmented the North America diabetic neuropathy treatment market based on peripheral neuropathy, autonomic neuropathy, proximal neuropathy, focal neuropathy covering the revenue growth of each sub-segment from 2018 to 2030.
- North America Diabetic Neuropathy Treatment Market Disorder Type Outlook (Revenue, USD Million , 2018-2030)
- Peripheral Neuropathy
- Autonomic Neuropathy
- Proximal Neuropathy
- Focal Neuropathy
- North America Diabetic Neuropathy Treatment Market Drug Class Outlook (Revenue, USD Million , 2018-2030)
- Capsaicin
- Opioid
- Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
- Antidepressants
- Other Drug Class
- North America Diabetic Neuropathy Treatment Market Distribution Channel Outlook (Revenue, USD Million , 2018-2030)
- Hospital Pharmacies
- Retail Pharmacies
- Others Distribution Channel
Reasons to subscribe to diabetic neuropathy treatment market report databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of diabetic neuropathy treatment market report databook
- Our clientele includes a mix of diabetic neuropathy treatment market report companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the North America diabetic neuropathy treatment market report, including forecasts for subscribers. This continent databook contains high-level insights into North America diabetic neuropathy treatment market report from 2018 to 2030, including revenue numbers, major trends, and company profiles.
North America Diabetic Neuropathy Treatment Market, 2018-2030 (US$M)
North America diabetic neuropathy treatment market report statistics, by disorder type, 2018-2030 (US$M)
